IMARC Group, a leading market research company, has recently released a report titled "Human Growth Hormone Market Share, Size, Trends and Forecast by Product, Material, Distribution Channel, Pricing, End-User, and Region, 2025-2033." The study provides a detailed analysis of the industry, including the Human Growth Hormone market size, share, trends, and growth forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Human Growth Hormone Market Overview

The global human growth hormone market was valued at USD 6.11 Billion in 2024. It is projected to reach USD 11.47 Billion by 2033, showing a compound annual growth rate (CAGR) of 6.88% during 2025-2033. North America leads with a 42.8% market share in 2024, driven by advanced healthcare infrastructure and the high incidence of hormone deficiencies. The market growth is fueled by biotechnology advances, aging population demand, technological innovation in delivery systems, and rising awareness.

Study Assumption Years

  • Base Year: 2024
  • Historical Year/Period: 2019-2024
  • Forecast Year/Period: 2025-2033

Human Growth Hormone Market Key Takeaways

  • The global human growth hormone market size was USD 6.11 Billion in 2024.
  • The market is forecasted to grow at a CAGR of 6.88% from 2025 to 2033.
  • North America held the largest market share of 42.8% in 2024.
  • Increasing incidences of growth hormone deficiencies such as Turner syndrome and Prader-Willi syndrome are major growth drivers.
  • Advancements in recombinant DNA technology have improved synthetic HGH production, accessibility, and affordability.
  • Technological improvements in drug delivery systems enhance patient compliance, such as long-acting formulations and easy-to-use devices.
  • The United States is a market disruptor with innovative long-acting HGH products and strong regulatory support.

Claim Your Free "Human Growth Hormone Market" Insights Sample PDF:  : https://www.imarcgroup.com/human-growth-hormone-market/requestsample

Market Growth Factors

The human growth hormone (HGH) market is significantly driven by the rising incidence of various growth hormone deficiencies, including hyposomatotropism, Turner syndrome, and Prader-Willi syndrome. Turner syndrome affects approximately one in 2,500 female babies and the administration of HGH helps reverse symptoms, increasing demand globally. Biotechnology and recombinant DNA technology advancements have enabled the production of synthetic HGH, which improves both the accessibility and affordability of treatments. This accessibility has driven broader market penetration and acceptance.

An aging global population further stimulates HGH demand due to hormone deficiencies associated with old age. Growth hormone deficiency causes symptoms like lost muscle mass and lethargy in adults, and HGH therapies are essential to manage these conditions. The increasing elderly demographic, including in markets such as the United States where the population aged 65 and above is projected to reach 82 million by 2050, contributes to heightened hormone replacement therapy needs.

Technological innovations in drug delivery systems represent another major growth factor. Historical limitations of frequent injections are being overcome by the development of long-acting HGH formulations, pen devices, transdermal patches, and auto-injectors, which improve patient ease and compliance. These advancements enable more stable hormone levels in the bloodstream, reducing side effects and enhancing efficacy. Furthermore, increasing awareness among patients and healthcare practitioners regarding the benefits of HGH therapy supports market expansion. Healthcare infrastructure improvements in developing countries create new growth opportunities, while the trend toward personalized medication and preventive healthcare continues to transform HGH treatment paradigms.

Market Segmentation

Analysis by Application:

  • Growth Hormone (GH) Deficiency
  • Adult GH Deficiency: Primarily manifests as lost muscle mass, lethargy, and declining metabolic function in adults. HGH offers effective treatment, ensuring steady demand.
  • Pediatric GH Deficiency: Can cause dwarfism and delayed puberty; early diagnosis and treatment are critical.
  • Turner Syndrome: A chromosomal disorder affecting females; HGH used to reverse symptoms and improve growth.
  • Idiopathic Short Stature (ISS): Not provided in source.
  • Prader-Willi Syndrome (PWS): Growth hormone administered to manage symptoms.
  • Small for Gestational Age: Not provided in source.
  • Others: Not provided in source.

Analysis by Distribution Channel:

  • Hospital Pharmacy: Leads with 47.9% market share in 2024; offers regulated, safe, and consistent HGH access under clinical supervision.
  • Retail Pharmacy: Not provided in source.
  • Online Pharmacy: Not provided in source.
  • Others: Not provided in source.

Analysis by Route of Administration:

  • Intravenous: Not provided in source.
  • Intramuscular: Not provided in source.
  • Subcutaneous: Leads with 33.7% market share in 2024; preferred for effectiveness, convenience, and patient compliance; self-administrable with advanced devices.
  • Oral: Not provided in source.

Regional Insights

North America dominates the human growth hormone market with a 42.8% share in 2024. The region benefits from developed healthcare infrastructure, strong R&D, high incidence of growth hormone deficiencies, and supportive reimbursement policies. The United States alone accounts for 91.80% of the North American market. Investments in innovation, regulatory support, and patient awareness position North America as the top HGH market region globally.

Recent Developments & News

  • February 2025: Kerala state government launched the KARE scheme providing free HGH therapy to children with growth hormone deficiencies to assist underprivileged families covering costs that can exceed INR 1 lakh annually.
  • December 2024: JCR Pharmaceuticals began a Phase III clinical trial in Japan for JR-142, a long-acting HGH targeting pediatric GH deficiency, comparing its efficacy to daily injections in 54 children over 52 weeks.
  • June 2023: US FDA approved Pfizer and OPKO Health's NGENLA, a long-acting HGH analog for children aged three and older, administered weekly subcutaneously, offering a less burdensome alternative to daily injections.

Key Players

  • Eli Lilly and Company
  • EMD Serono Inc.
  • Hoffmann-La Roche AG
  • Ferring B.V.
  • Genentech Inc.
  • Ipsen
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk
  • Pfizer Inc.
  • Sandoz

Ask an Analyst : https://www.imarcgroup.com/request?type=report&id=2052&flag=C

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: [email protected]

Tel No: (D) +91 120 433 0800

United States: +1-201971-6302